TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05176158
Drug: Dexketoprofen 25 MG
Normalized name: dexketoprofen 25 MG
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill at night
Study: NCT00002366
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05298332
Drug: ATI-2173 50 mg
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
Study: NCT06104358
Drug: HU6
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HU6 is being evaluated for its effect on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function
Study: NCT06697353
Drug: vericiguat (BAY 1021189)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg initiating dose
Study: NCT06697197
Drug: BMS-986482
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06547736
Drug: SHR-A1904 or/and HRS-4642
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Study: NCT06697197
Drug: Nivolumab and rHuPH20
Normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06697197
Drug: Nivolumab/relatlimab/rHuPH20
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06697197
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06698003
Drug: Mogamulizumab
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
Study: NCT05695495
Drug: N,N-Dimethyltryptamine (5mg)
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus application over 45 seconds
Study: NCT05695495
Drug: N,N-Dimethyltryptamine (10mg)
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus application over 45 seconds
Study: NCT05695495
Drug: N,N-Dimethyltryptamine (15mg)
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus application over 45 seconds
Study: NCT05695495
Drug: N,N-Dimethyltryptamine (20mg)
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus application over 45 seconds
Study: NCT05695495
Drug: N,N-Dimethyltryptamine (25mg)
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus application over 45 seconds
Study: NCT05134649
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular Injection
Study: NCT06519565
Drug: PRG-1801
Normalized name: PRG-A01
DrugBank: PRG-A01 (DB18613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRG-1801 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA. Participants will undergo leukapheresis to collect mononuclear cells for PRG-1801 manufacturing. Prior to infusion, patients receive lymphodepletion with cyclophosphamide (250-300 mg/m2/day) and fludarabine (25-30 mg/m2/day) for 3 days. PRG-1801 is then administered as a single intravenous infusion at one of three dose levels: 35×10\^6, 100×10\^6, or 300×10\^6 CAR-T cells. Premedication with antipyretics and antihistamines is given 30-60 minutes before infusion. The infusion rate is 2-5 ml/min. Patients are monitored for safety and efficacy for up to 24 months post-infusion. Some patients may be eligible for a second infusion if they respond initially but later relapse.
Study: NCT04934683
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic induction with etomidate.
Study: NCT04934683
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic induction with propofol.
Study: NCT05063201
Drug: Cariprazine 1.5 MG
Normalized name: cariprazine 1.5 MG
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
Study: NCT06011083
Drug: Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
Study: NCT05472792
Drug: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
Study: NCT05730842
Drug: EDG-5506 Tablet
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral Dose - Tablet
Study: NCT05730842
Drug: Radiolabeled EDG-5506 Suspension
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Oral Dose
Study: NCT05730842
Drug: Radiolabeled EDG-5506 Intravenous
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Intravenous Dose
Study: NCT06084364
Drug: Injection of triamcinolone acetonide into the CMC-1 joint
Normalized name: triamcinolone acetonide Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraarticular injection with triamcinolone acetonide
Study: NCT04883138
Drug: GIGA-2050
Normalized name: Hippoglossus gigas flesh
DrugBank: Atlantic halibut (DB15549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Hyperimmune Polyclonal Antibody
Study: NCT05448456
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gram of tranexamic acid in 100 ml of 0.9% normal saline
Study: NCT05511779
Drug: Brincidofovir
Normalized name: Brincidofovir
DrugBank: Brincidofovir (DB12151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
Study: NCT05019209
Drug: House Dust Mite Allergen
Normalized name: house dust mite allergen extract
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
Study: NCT06014762
Drug: Rimiducid
Normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single weight-based IV administration
Study: NCT05009901
Drug: Alpha Lipoic Acid 600 MG Oral Tablet
Normalized name: alpha lipoic acid 600 mg ORAL TABLET
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid 600 mg daily for 8 weeks
Study: NCT05600075
Drug: microneedling with topical glycolic acid 35%.
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
Study: NCT05226546
Drug: Platelet rich plasma (PRP)
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
Study: NCT06032039
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard treatment for osteoarthritis knee pain
Study: NCT05542264
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
Study: NCT05542264
Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Normalized name: Priorix
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
Study: NCT06309667
Drug: PG-102(MG12)
Normalized name: PG
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLP-1 and GLP-2 fusion protein
Study: NCT05756322
Drug: LBS-007
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open Label.
Study: NCT05036135
Drug: AV-101
Normalized name: AV-101
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (imatinib) administered via dry powder inhalation
Study: NCT05646082
Drug: Dostarlimab in Combination Antiretroviral Therapy
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
Study: NCT04592809
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infused over a 40 minute period
Study: NCT04592809
Drug: Midazolam Hydrochloride
Normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: infused over a 40 minute period
Study: NCT05221892
Drug: Ginger
Normalized name: Ginger
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to be taken 30 minutes before each of 4 trips.
Study: NCT06214403
Drug: MET-2
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
Study: NCT06501924
Drug: Topical minoxidil 5%
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical minoxidil 5%
Study: NCT06501924
Drug: DA-002
Normalized name: CENPLACEL-L COMPONENT OF PDA-002
DrugBank: Cenplacel-L (DB19188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Alpha 1 Agonist (GRAS)
Study: NCT06325956
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Take metformin for six months.
Study: NCT06586281
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.
Study: NCT06546839
Drug: SAPB block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the lateral decubitus position, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane concerning the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be injected for correction. Following confirmation of the correct position of the needle, 30 ml %0.25 bupivacaine will be administered for the block.
Study: NCT05068349
Drug: Butylphthalide
Normalized name: BUTYLPHTHALIDE
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
Study: NCT05506254
Drug: hLB-001
Normalized name: SUCROSE DISTEARATE (HLB 5)
DrugBank: LB-001 (DB17685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hLB-001 gene therapy
Study: NCT04778592
Drug: ETX-018810
Normalized name: Polygonatum biflorum root etxract
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT04734457
Drug: Levothyroxin
Normalized name: Levothyroxin
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
Study: NCT06110403
Drug: TRIXEO AEROSPHERE
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
Study: NCT05718258
Drug: Venglustat (GZ402671)
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT06701305
Drug: Efinopegdutide
Normalized name: Efinopegdutide
DrugBank: Efinopegdutide (DB15077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injectable solution
Study: NCT05469919
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib taken orally
Study: NCT06464770
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
Study: NCT05485558
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
Study: NCT05485558
Drug: NAc
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
Study: NCT06480201
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine infusion amount is dictated by BMI, sex, and age.
Study: NCT05525910
Drug: Nirmatrelvir/ ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
Study: NCT05525910
Drug: Nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
Study: NCT05855018
Drug: Atropine sulfate eye drops
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop once daily
Study: NCT06521216
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all patients will receive 200 mg elemental iron (ferrous sulphate)
Study: NCT05357040
Drug: Nitrous oxide gas for inhalation
Normalized name: nitrous oxide Gas for Inhalation
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study: NCT05162586
Drug: Enpatoran low dose
Normalized name: ethinyl estradiol
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
Study: NCT05162586
Drug: Enpatoran medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
Study: NCT05162586
Drug: Enpatoran high dose
Normalized name: high-density polyethylene
DrugBank: Enpatoran (DB16501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
Study: NCT05895994
Drug: RD13-02 cell infusion
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cells
Study: NCT06486883
Drug: Trastuzumab deruxtecan (T-DXd, DS-8201a)
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
Study: NCT05340413
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg twice daily
Study: NCT05631847
Drug: Intravenous thrombolysis (Alteplase)
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
Study: NCT00002433
Drug: Interferon gamma-1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05894421
Drug: TQB2223 injection+ Penpulimab Injection
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
Study: NCT05199753
Drug: LM-108
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05199753
Drug: An Anti-PD-1 Antibody
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06398873
Drug: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg/2 weeks
Study: NCT04749914
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT04749914
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06102083
Drug: TDI01 suspension
Normalized name: TDI01
DrugBank: TDI-01 (DB19450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily.
Study: NCT06676280
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take aspirin 100 mg/day.
Study: NCT06440252
Drug: Grape Seed Extract
Normalized name: Grape Seed Extract
DrugBank: Vitis vinifera seed (DB16606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily dose of 1 capsule containing 600mg grape seed extract
Study: NCT06440252
Drug: Maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily dose of 1 capsule
Study: NCT06707922
Drug: Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Peginterferon α-2b Injection, subcutaneous injection, once a week. Tenofovir Alafenamide Fumarate, Oral administration, once a day.